Orion Biotech Opportunities Corp. Class A Ordinary Share
ORIA
ORIA was delisted on the 28th of April, 2023.
27 hedge funds and large institutions have $86.2M invested in Orion Biotech Opportunities Corp. Class A Ordinary Share in 2021 Q3 according to their latest regulatory filings, with 27 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
+$11.7M |
| 2 |
FTCM
Fir Tree Capital Management
New York
|
+$9.76M |
| 3 |
MI
MMCAP International
Grand Cayman,
Cayman Islands
|
+$7.81M |
| 4 |
SCC
Spring Creek Capital
Wichita,
Kansas
|
+$7.81M |
| 5 |
ACA
Arena Capital Advisors
Los Angeles,
California
|
+$5.86M |
Top Sellers
ORIA Hedge Fund Activity: Q3 2021 in Review
27 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Orion Biotech Opportunities Corp. Class A Ordinary Share (ORIA) for Q3 2021, worth a combined $86.2M.
Buyers outnumbered sellers: 27 funds opened new ORIA positions and 0 closed out — a net gain of 27 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was 683 Capital Management, opening a new position worth an estimated $11.7M.
- 27 institutional investors held Orion Biotech Opportunities Corp. Class A Ordinary Share (ORIA) as of Q3 2021, up from 0 in Q2 2021.
- Funds reported $86.2M of Orion Biotech Opportunities Corp. Class A Ordinary Share stock for Q3 2021.
- 27 funds opened new Orion Biotech Opportunities Corp. Class A Ordinary Share positions in Q3 2021 and 0 closed out, a net change of +27 holders.
- The largest Orion Biotech Opportunities Corp. Class A Ordinary Share buyer in Q3 2021 was 683 Capital Management, an estimated $11.7M added.
Based on aggregated 13F filings for Q3 2021.